HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acquired hypoprothrombinemia: effects of danazol treatment.

Abstract
The lupus anticoagulant may be accompanied by an acquired factor II deficiency and bleeding. We report on a patient with a lupus anticoagulant and factor II (Fll) deficiency responsive to Danazol. Acquired hypoprothrombinemia (FII) with the lupus anticoagulant (LA) may be accompanied by a hemorrhagic diathesis. A 64-year-old male with discoid lupus erythematosis bled after an intestinal polypectomy. His FII level was 18%, and his FII antigen level was 20%. Danazol (D) (600 mg per day) administration was associated with a rise in FII activity and antigen to 50% within 10 days. The patient underwent abdominal surgery. We studied the effect(s) of D on the FII level and on other coagulation factors in this patient. The patient's plasma FII antigen had a single precipitin arc compared to the two peaks of normal plasma on counterimmunoelectrophoresis with Ca++. The samples pre- and during D therapy had the same positively charged arc as normal samples, although they were quantitatively different. Neuraminidase treatment demonstrated a decrease in the positively charged migration of normal and the patient's FII antigen. Affinity chromatography of normal and patient plasma on a Sepharose protein A column revealed FII antigen present in the patient's bound fraction. The relative percentages of bound FII before and during D treatment were similar. During D therapy, levels of FIX and X rose 50-100%, and protein C rose 20-25%, while free protein S did not change. D is an effective therapy for acquired FII deficiency associated with LA. D does not affect the binding of Ig to FII, but D raises FII levels by increasing synthesis of the FII protein.
AuthorsS Williams, C Linardic, O Wilson, P Comp, H R Gralnick
JournalAmerican journal of hematology (Am J Hematol) Vol. 53 Issue 4 Pg. 272-6 (Dec 1996) ISSN: 0361-8609 [Print] United States
PMID8948670 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Lupus Coagulation Inhibitor
  • Danazol
Topics
  • Blood Loss, Surgical (prevention & control)
  • Colonic Polyps (surgery)
  • Danazol (therapeutic use)
  • Humans
  • Hypoprothrombinemias (drug therapy, etiology, immunology)
  • Lupus Coagulation Inhibitor (immunology)
  • Lupus Erythematosus, Discoid (complications, immunology)
  • Male
  • Middle Aged
  • Prothrombin Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: